Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Eperisone HCl in the Treatment of Acute Musculoskeletal Spasm Associated With Low Back Pain - A Double Blind, Randomised, Placebo Controlled Clinical Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00327730
Recruitment Status : Completed
First Posted : May 18, 2006
Last Update Posted : April 21, 2014
Sponsor:
Collaborator:
Eisai Co., Ltd.
Information provided by (Responsible Party):
Eisai Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate the efficacy of Eperisone HCl in the treatment of Acute Musculoskeletal spasm associated with Low-Back Pain.

Condition or disease Intervention/treatment Phase
Muscle Spasm; Back Pain Drug: Eperisone Phase 3

Detailed Description:
This is a multi-center trial, which will be conducted in a total of 240 patients (120 patients in each treatment group). Patients attending the out-patient setting of traumatology and orthopedic departments of the study centers will be screened for lumbar pain and spasm by clinical and radiological examination for inclusion. In this study, it has been planned to enroll a total of 240 patients with 120 patients in each group. The total duration of treatment will be 14 days. Patients will be screened for baseline parameters and will then be randomized, as per the predetermined randomization schedule, into two groups. Patients will be treated with either Eperisone-HCl (Myonal) or placebo for a period of 14 days. After the baseline-screening visit (Day 1), the patients would be asked to follow up on day 3, day 7, and day 14. During each visit, a complete general examination and clinical evaluation of efficacy parameters would be done. Adverse events would be monitored during the study period and would be recorded in the Case Report Form (CRF). At the end of the treatment, Global Assessment of Response to Therapy by Physicians and Patients (PGART) would be done for efficacy and tolerability separately.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of Eperisone HCl in the Treatment of Acute Musculoskeletal Spasm Associated With Low Back Pain
Study Start Date : April 2006
Actual Primary Completion Date : June 2006
Actual Study Completion Date : June 2006

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. The present study will be conducted with an objective of comparing the efficacy of Eperisone-HCl (Myonal) versus placebo in the treatment of acute musculoskeletal spasm associated with low back pain.

Secondary Outcome Measures :
  1. The present study will be conducted with a secondary objective of comparing the tolerability of Eperisone-HCl (Myonal) versus placebo.

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients of either sex between 18 to 60 years of age.

  2. Patients with confirmed diagnosis of Acute Musculoskeletal spasm with Low Back Pain due to:

    • Spondylosis deformans
    • Prolapsed Intervertebral Disc (PID)
    • Muscle sprains with spasms
  3. Patients who are willing to take the medications as directed and willing to come for follow-ups.
  4. Patients who are willing to comply with the protocol requirements.
  5. Patients who are willing to give the written informed consent.

Exclusion Criteria:

  1. Patients with other associated spasm conditions like:

    • Muscle sprains with spasms of hip/knee/ankle
    • Traumatic pain with spasms
    • Cervical Spondylitis
    • Pain & spasm associated with fractured bone.
  2. Patients who had taken any form of skeletal muscle relaxant in the previous 7 days.
  3. Patients with hypersensitivity to any of the ingredients of the test & control formulations.
  4. Pregnant/Lactating women or women of child bearing potential not following adequate contraceptive measures.
  5. Patients unwilling or unable to comply with the study procedures.
  6. Patients having a history of severe acute infection, major surgery or trauma, severe metabolic, endocrine or electrolyte disturbances and seizures in preceding 8 weeks.
  7. Patients having severe renal insufficiency defined by a creatinine value above 2.5 mg/dl.
  8. Patients having severe hepatic insufficiency defined by an SGOT or SGPT value equal or higher than the threefold normal values of the respective laboratory reference value.

  9. Patients having any of the following disorders:

    • Renal failure
    • Bulimia
    • Hypo and Hyperthyroidism
    • Nephrotic syndrome
    • Anorexia nervosa
    • Biliary obstruction
    • Severe cardiac dysfunction.
  10. Patients having uncontrolled diabetes mellitus, or any other metabolic or endocrine disorder.
  11. Patients that have received treatment with any investigational drug in the preceding 4 weeks.
  12. Patients likely to be non-compliant (alcohol, smoking or drug abusers).
  13. Any condition that, in the opinion of the investigator, does not justify patient's inclusion in the study.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00327730


Locations
Layout table for location information
India
M.R. Medical College
Gulbarga, Karnataka, India, 585 104
Grant Medical College Sir J.J. Group of Hospitals
Byculla, Mumbai, Maharashtra, India, 400 008
L.T. M. Medical College and General Hospital
Sion, Mumbai, Maharashtra, India, 400 022
Post Graduate Institute of Medical Education and Research (PGI)
Chandigarh, Punjab, India, 160 012
Sponsors and Collaborators
Eisai Inc.
Eisai Co., Ltd.
Investigators
Layout table for investigator information
Study Director: Dr. Dilip Pawar Eisai Pharmaceuticals India Pvt. Ltd
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Eisai Inc.
ClinicalTrials.gov Identifier: NCT00327730    
Other Study ID Numbers: E0646-AS91-301
First Posted: May 18, 2006    Key Record Dates
Last Update Posted: April 21, 2014
Last Verified: April 2014
Keywords provided by Eisai Inc.:
Muscle
Spasm
Back
Pain
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscle Cramp
Spasm
Back Pain
Low Back Pain
Pain
Neurologic Manifestations
Neuromuscular Manifestations
Nervous System Diseases
Muscular Diseases
Musculoskeletal Diseases
Eperisone
Anticonvulsants
 Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Muscle Relaxants, Central
Neuromuscular Agents
Peripheral Nervous System Agents
Parasympatholytics
Autonomic Agents
Vasodilator Agents